Replies to post #38675 on $heff's $tation of $tocks & $olid DD

[Stock H.O.G.]

In an almost $2B market with a significant reduction in side effects such as dizziness and somnolence, as well as a more convenient once daily (QD) dosing profile versus the 3-4x daily for generic gabapentin.....if it's not ABT, another biggie will jump on board. DEPO alredy has 2 drugs approved and selling, so it's not their 1st go around here. They also have other drugs in the pipeline, including a significant one in Phase III. This is not a one hit wonder company.

[$heff]

oldberkeley...DEPO ($5.73) we will see there. Abbott didn't just decide now that they were going to pull out before approval based on the fact the product won't sell. They want a better deal than what they have and I. No one really knows what Abbott is thinking as they have not communicated clearly with Depomed but the timing of the announcement is suspect. Abbott has not given detailed comments on it so know one really knows their stance on the issue. We already know the possible scenarios from the conference call yesterday from Depomed's point of view. We will see what happens moving forward.

Message in reply to:

ABT scientists and execs are not stupid; as many have pointed out, the timing of their announcement certainly suggests that they feel approval is likely and they wanted to put their cards on the table now.

Many, many bios with good, approved drugs; unfortunately, the market says, "That's nice. Now how are you going to sell it?"

That's DEPO's problem here.

[hvypilot]

Yes, agree ABT execs not stupid. Isn't it possible they think the market for DEPO's drug, given that its competing with a generic, is too weak to pursue?

No one here wants to look at the bear case. I'm not qualified to know, but no one here really seems to be addressing the possibility.